Sam Lee

20120183496, Jul 19, 2012

Dec 16, 2011

13/328036

Sam SK Lee - Lynnwood WA, US
Wang Shen - San Mateo CA, US
Xiaoling Zheng - Fremont CA, US
Irina C. Jacobson - Sammamish WA, US

COCRYSTAL DISCOVERY, INC. - Bothell WA

A61K 31/4436
C07D 487/04
A61K 31/519
C07D 417/14
C07D 409/14
A61K 31/444
A61K 31/497
C07D 413/14
C07D 498/04
C07D 471/04
A61K 31/4709
A61K 38/21
A61K 31/7056
A61P 31/14
A61K 31/4439
C07D 409/04

424 854, 5462804, 514336, 544281, 5142593, 546256, 514333, 544405, 51425505, 544263, 51425931, 546115, 514302, 546118, 514303, 546176, 514314, 514 43, 5462697, 514342, 5462754, 514341, 5462714, 514340, 5462721, 5462747, 5462774, 514339, 5462757, 546119

The present invention provides, among other things, compounds represented by the general Formula I:and pharmaceutically acceptable salts thereof, wherein X, Y, R, R, R, and Rare as defined in classes and subclasses herein and compositions (e.g., pharmaceutical compositions) comprising such compounds, which compounds are useful as inhibitors of hepatitis C virus polymerase, and thus are useful, for example, as medicaments for the treatment of HCV infection.

20220401536, Dec 22, 2022

Jun 16, 2022

17/842235

Sam LEE - Bellevue WA, US

A61K 39/00

Provided herein are compositions and methods for treating immune diseases or disorders, including cancer. In some embodiments, the compositions and methods are directed to the use of anti-DD1α antibodies to modulate the immune-regulatory activity of DD1α, thereby promoting anti-tumor immunity. Methods for identifying patients that are likely to respond to anti-DD1α therapy, and for treating such patients with anti-DD1α antibody compositions are also provided.

20210393629, Dec 23, 2021

Nov 13, 2019

17/292863

- Bothell WA, US
Liang Mao - Shanghai, CN
Irina C. Jacobson - Sammamish WA, US
Sam SK Lee - Edmonds WA, US

A61K 31/506
A61K 9/00
A61K 9/16

Provided herein are compositions of an antiviral therapeutic to treat influenza suitable for administration via inhalation.

20210353629, Nov 18, 2021

Oct 17, 2019

17/286026

- Bothell WA, US
Biing Yuan Lin - Bellevue WA, US
Sam SK Lee - Edmonds WA, US

A61K 31/519
A61K 39/145
A61K 45/06

Provided herein are combinations of compounds that can inhibit the replication of influenza viruses, reduce the amount of influenza viruses, and/or treat influenza.

20210161935, Jun 3, 2021

May 9, 2019

17/047209

- Bothell WA, US
Biing Yuan Lin - Bellevue WA, US
Sam SK Lee - Edmonds WA, US

A61K 31/7072
A61K 31/4439
A61K 31/498
A61K 31/4188
A61P 31/14

Disclosed herein are combination therapies for use in the treatment or prevention of HCV by administering Compound A and a second HCV inhibitor.

20210121462, Apr 29, 2021

Jul 26, 2019

17/259397

- Bothell WA, US
Sam SK Lee - Edmonds WA, US
Michael David Feese - Seattle WA, US

A61K 31/506
A61K 45/06
A61K 39/145
C07D 471/04
A61P 31/16

Provided herein are compounds of Formula A, B or C that can inhibit the replication of influenza viruses, reduce the amount of influenza viruses, and/or treat influenza.

20200255393, Aug 13, 2020

Sep 25, 2019

16/582468

- Bothell WA, US
Michael D. Feese - Seattle WA, US
Sam S.K. Lee - Edmonds WA, US

C07D 307/84
A61K 31/343
A61K 45/06

The present invention provides, among other things, compounds represented by the general Formula I: (I) and pharmaceutically acceptable salts thereof, wherein L and A (and further substituents) are as defined in classes and subclasses herein and compositions (e.g., pharmaceutical compositions) comprising such compounds, which compounds are useful as inhibitors of hepatitis C virus polymerase, and thus are useful, for example, as medicaments for the treatment of HCV infection.

20200123177, Apr 23, 2020

Apr 24, 2018

16/603951

- Bothell WA, US
Michael David Feese - Seattle WA, US
Sam SK Lee - Edmonds WA, US

C07D 519/00
A61K 9/00
A61K 9/127
A61K 9/14
A61P 31/16

Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient a safe and effective amount of a compound represented by any of Formulas I-III, or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a safe and effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.